Summary & Overview
Local Excision and Removal of Internal Fixation Devices Except Hip and Femur without CC/MCC: Inpatient Reimbursement Overview
DRG 497 encompasses local excision and removal of internal fixation devices except hip and femur without Complication or Comorbidity or Major Complication or Comorbidity; it is used to classify relatively uncomplicated hardware removal inpatient stays. This grouping matters for inpatient reimbursement because it assigns a lower payment weight than cases with Complication or Comorbidity or Major Complication or Comorbidity and depends on accurate procedural and diagnosis coding for Medicare payment.
DRG 497 Overview
DRG 497 covers inpatient cases involving local excision and removal of internal fixation devices, excluding procedures on the hip and femur, without Complication or Comorbidity or Major Complication or Comorbidity. It applies to patients undergoing removal of plates, screws, rods, or other hardware from non-hip, non-femur sites when no additional complicating diagnoses are coded. This Diagnosis-Related Group matters for Medicare payment because it groups relatively straightforward hardware removal procedures into a lower-weighted payment category compared with cases that include Complication or Comorbidity or Major Complication or Comorbidity. Proper coding of the principal procedure and concurrent diagnoses determines enrollment in this Diagnosis-Related Group and thus the inpatient reimbursement class.
Clinical Trials
- Acute perioperative infection prevention trials: Randomized or prospective cohort studies testing protocols (for example, optimized perioperative antibiotic timing, wound care regimens, or antiseptic strategies) in patients undergoing local excision or removal of internal fixation devices of the extremities (excluding hip and femur). These studies enroll primarily post-trauma or post-orthopedic-surgery patients who require device removal and are at risk for surgical-site infection, and they measure short-term outcomes such as infection rates, reoperation, and length of stay. This research is relevant to providers and payers because reducing infections and readmissions in the immediate inpatient period can lower costs and improve DRG-level quality metrics.
- Comparative effectiveness studies of surgical approach and anesthesia in device removal and local excision: Pragmatic trials or large registry-based comparative studies comparing different surgical techniques (open versus limited incision, use of image guidance, hardware extraction tools) and anesthesia strategies (regional block versus general anesthesia) in adults undergoing removal of internal fixation devices of the forearm, wrist, ankle, or other non-hip/femur sites. These studies focus on intraoperative outcomes, perioperative complications, operative time, and functional recovery up to 30–90 days, often stratified by comorbidity burden and indication for removal (pain, prominence, infection, nonunion). Findings inform clinicians about which approaches optimize efficiency and outcomes for typical DRG 497 patients, supporting care pathways and resource allocation decisions important to payers.
- Post-discharge functional and cost-outcomes research: Observational cohort studies and prospective longitudinal studies following patients discharged after local excision or hardware removal to assess long-term wound healing, pain control, return-to-work or activity, use of outpatient physical therapy, and healthcare utilization (ED visits, readmissions, additional procedures) over months to a year. These studies target heterogeneous patients—including elderly with comorbidities and younger working-age adults—to identify predictors of poorer recovery and high downstream costs, and to evaluate interventions such as structured discharge planning or targeted rehabilitation. Results help payers and hospital systems design post-acute care pathways and bundled-payment strategies to reduce avoidable downstream utilization associated with DRG 497 cases.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.